Skip to content
Screener

Regeneron Pharmaceuticals REGN Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$22.53M+3.2%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$2.55M+34.4%
Precigen logo
PrecigenPGEN
$1.07M+15.1%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$3.17M+47.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$11.66M+6.5%
Annexon logo
AnnexonANNX
$3.02M+15.3%

Other financials

Income statement

See full
Revenue$4.3B+16.7%
Operating income$1.3B+19.8%
Net income$1.3B-6.8%
EPS (diluted)$12.23-4.5%

Balance sheet

See full
Cash & equivalents$2.5B+22.3%
Total debt$2.7B+0.1%
Total equity$31.7B+5.9%
Total assets$41.7B+9.2%

Cash flow

See full
Operating cash flow$813.0M-29.0%
CapEx$240.2M+9.7%
Free cash flow$572.8M-38.1%

Valuation

See full
Market cap$80.75B+39.6%
Enterprise value$80.99B+38.3%
P/E18.7×+5.7×
P/S5.2×+1.1×

Profitability

See full
Gross margin94.9%
Operating margin24.7%-2.3pp
Net margin27.9%-3.5pp
FCF margin24.2%-2.9pp

Returns & leverage

See full
Return on equity14%-1.3pp
Debt / equity0.1×0.0×
Current ratio3.3×-1.3×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Regeneron Pharmaceuticals’s 10-K, filed February 4, 2026.

Filed
Feb 4, 2026, 9:08 AM EST
Fiscal year
FY2025
Accession
0000872589-26-000008
(In millions)ClassificationAs of December 31, 2025As of December 31, 2024
$822.5$808.6
Liabilities:
Finance lease liabilities - noncurrentFinance lease liabilities$720.0$720.0
Operating lease liabilities - currentAccrued expenses and other current liabilities37.830.3
Operating lease liabilities - noncurrentOther noncurrent liabilities229.0204.1
$986.8$954.4
(a) Finance lease right-of-use assets were recorded net of accumulated amortization of $162.9 million and $148.4 million as of December 31, 2025 and 2024, respectively
(b) Operating lease right-of-use assets were recorded net of accumulated amortization of $68.8 million and $78.4 million as of December 31, 2025 and 2024, respectively

Item 16. Form 10-K Summary

FAQ

What is Regeneron Pharmaceuticals's operating lease liabilities (current)?
Regeneron Pharmaceuticals (REGN) reported operating lease liabilities (current) of $37.8M in Q4 2025.
What is the long-term trend for Regeneron Pharmaceuticals's operating lease liabilities (current)?
Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's operating lease liabilities (current) has grown at a 45.0% compound annual growth rate (CAGR), from $12.4M to $37.8M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Regeneron Pharmaceuticals's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude